Last reviewed · How we verify

Floseal hemostatic matrix

Chang Gung Memorial Hospital · FDA-approved active Small molecule Under review

Floseal hemostatic matrix is a Hemostatic agent Small molecule drug developed by Chang Gung Memorial Hospital. It is currently FDA-approved for Hemostasis during surgical procedures where bleeding control is needed, Adjunctive hemostatic agent in general, cardiac, and vascular surgery. Also known as: Floseal.

FloSeal is a hemostatic matrix that combines gelatin and thrombin to form a biologically active scaffold that promotes rapid clot formation and hemostasis at surgical bleeding sites.

Floseal hemostatic matrix is used to control bleeding during laparoscopic cholecystectomy in acute cholecystitis and as a treatment for epistaxis. The exact mechanism of action of Floseal is unknown.

At a glance

Generic nameFloseal hemostatic matrix
Also known asFloseal
SponsorChang Gung Memorial Hospital
Drug classHemostatic agent
TargetThrombin-mediated fibrin formation
ModalitySmall molecule
Therapeutic areaHemostasis / Surgical bleeding control
PhaseFDA-approved

Mechanism of action

FloSeal works by providing a three-dimensional gelatin matrix that is cross-linked with thrombin, a key coagulation enzyme. When applied to bleeding surfaces, the gelatin matrix absorbs blood and concentrates coagulation factors while thrombin directly catalyzes fibrin formation, accelerating the natural clotting cascade. This dual mechanism creates a stable clot that adheres to the wound site and is gradually absorbed as healing progresses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Floseal hemostatic matrix

What is Floseal hemostatic matrix?

Floseal hemostatic matrix is a Hemostatic agent drug developed by Chang Gung Memorial Hospital, indicated for Hemostasis during surgical procedures where bleeding control is needed, Adjunctive hemostatic agent in general, cardiac, and vascular surgery.

How does Floseal hemostatic matrix work?

FloSeal is a hemostatic matrix that combines gelatin and thrombin to form a biologically active scaffold that promotes rapid clot formation and hemostasis at surgical bleeding sites.

What is Floseal hemostatic matrix used for?

Floseal hemostatic matrix is indicated for Hemostasis during surgical procedures where bleeding control is needed, Adjunctive hemostatic agent in general, cardiac, and vascular surgery.

Who makes Floseal hemostatic matrix?

Floseal hemostatic matrix is developed and marketed by Chang Gung Memorial Hospital (see full Chang Gung Memorial Hospital pipeline at /company/chang-gung-memorial-hospital).

Is Floseal hemostatic matrix also known as anything else?

Floseal hemostatic matrix is also known as Floseal.

What drug class is Floseal hemostatic matrix in?

Floseal hemostatic matrix belongs to the Hemostatic agent class. See all Hemostatic agent drugs at /class/hemostatic-agent.

What development phase is Floseal hemostatic matrix in?

Floseal hemostatic matrix is FDA-approved (marketed).

What are the side effects of Floseal hemostatic matrix?

Common side effects of Floseal hemostatic matrix include Allergic reaction, Infection at surgical site, Hematoma formation, Seroma.

What does Floseal hemostatic matrix target?

Floseal hemostatic matrix targets Thrombin-mediated fibrin formation and is a Hemostatic agent.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing